Zitek Tony, Hashemi Mani, Zagroba Sara, Slane Valori H
Department of Emergency Medicine, Mount Sinai Medical Center, Miami Beach, FL, USA.
Department of Emergency Medicine, Kendall Regional Medical Center, Miami, FL, USA.
Open Access Emerg Med. 2022 Jul 28;14:367-373. doi: 10.2147/OAEM.S373335. eCollection 2022.
Acute aortic dissection (AAD) is a highly fatal disorder if not promptly diagnosed. Some international studies have suggested that serum d-dimer levels may be used to exclude AAD, but data are limited. We sought to confirm that d-dimer levels are elevated in American patients with AAD. Additionally, we sought to estimate the test characteristics of the d-dimer for AAD.
We performed a retrospective analysis of patients in the Hospital Corporation of America database who arrived at the hospital between 2015 and 2019. We queried the database to find patients who had a diagnosis of AAD or (nonspecific) chest pain, and who also had a d-dimer performed within 24 hours of arrival at the hospital. The median d-dimer was compared in those diagnosed with AAD versus chest pain. We estimated the test characteristics of d-dimer for AAD at the standard cutoff value of 500 ng/mL.
In total, 48,902 patients met the criteria for analysis, including 572 with AAD and 48,330 with chest pain. The median d-dimers were 2455 ng/mL and 385 ng/mL for the AAD and chest pain groups, respectively (p < 0.0001). Using a cutoff of 500 ng/mL, the sensitivity of the d-dimer was 91.1% and the specificity was 71.4%.
Serum d-dimer values are higher in patients with AAD than in those with nonspecific chest pain. At the standard cutoff of 500 ng/mL, the serum d-dimer has a high sensitivity for AAD, but not high enough that d-dimer levels alone can be used in isolation to exclude AAD.
急性主动脉夹层(AAD)若不及时诊断,是一种致死率很高的疾病。一些国际研究表明,血清D-二聚体水平可用于排除AAD,但相关数据有限。我们试图证实美国AAD患者的D-二聚体水平升高。此外,我们还试图评估D-二聚体检测AAD的特征。
我们对美国医院集团数据库中2015年至2019年入院的患者进行了回顾性分析。我们查询数据库以找出诊断为AAD或(非特异性)胸痛且在入院后24小时内进行了D-二聚体检测的患者。比较了诊断为AAD与胸痛患者的D-二聚体中位数。我们在500 ng/mL的标准临界值下评估了D-二聚体检测AAD的特征。
共有48,902例患者符合分析标准,其中572例为AAD患者,48,330例为胸痛患者。AAD组和胸痛组的D-二聚体中位数分别为2455 ng/mL和385 ng/mL(p<0.0001)。以500 ng/mL为临界值,D-二聚体的敏感性为91.1%,特异性为71.4%。
AAD患者的血清D-二聚体值高于非特异性胸痛患者。在500 ng/mL的标准临界值下,血清D-二聚体对AAD具有较高的敏感性,但敏感性还不足以仅依据D-二聚体水平来排除AAD。